Sign in
Stories
Antibe's Receivership and Delisting
Share
Advancements in Cancer Treatment and Mar...
BioPharma Shift: Coherus-Sandoz Acquisit...
Biopharma Companies Announce Public Offe...
ANJESO Drug Insight and Market Forecast
Acquisition Progress Amid Safety Concern
Adicet Bio Awards Stock Options
Overview
API
Antibe Therapeutics Inc. faces receivership and delisting as the Ontario Superior Court appoints a receiver, leading to the resignation of board members and a forthcoming delisting of common shares from TSX.
Ask a question
How might the appointment of a receiver impact Antibe's ongoing operations and strategic decisions?
In what ways could the delisting of common shares affect Antibe's market value and investor confidence?
What factors led to the resignation of five board members during this critical period for Antibe?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage